Overview
Danoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.
Indication
本品应与利托那韦、聚乙二醇干扰素α和利巴韦林联合组成抗病毒治疗方案，用于治疗初治的非肝硬化的基因1b型慢性丙型肝炎成人患者。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2017/12/05 | Phase 2 | Completed | |||
2017/09/20 | Phase 1 | Completed | |||
2017/01/13 | Phase 2 | Completed | |||
2017/01/13 | Phase 3 | Completed | |||
2017/01/13 | Phase 1 | Completed | |||
2017/01/13 | Phase 1 | Completed | |||
2017/01/13 | Phase 2 | Completed | |||
2012/12/13 | Phase 2 | Completed | |||
2012/10/25 | Phase 1 | Completed | |||
2012/07/31 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Danoprevir Sodium Tablets | 国药准字H20180008 | 化学药品 | 片剂 | 1/18/2023 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.